Patents by Inventor Michel Lagarde

Michel Lagarde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACEFAPC FOR THE TREATMENT OF ACETYLCHOLINE-DEPENDENT DISEASES
    Publication number: 20220273682
    Abstract: The present invention relates to AceFaPC (1-Acetyl-2-Fatty acyl-glyceroPhosphoCholine) for use in the prevention and treatment of diseases associated with an acetylcholine deficiency. The invention also relates to the AceFaPC molecule in which Fa represents an unsaturated acyl comprising at least 14 carbon atoms, and the pharmaceutical compositions comprising same.
    Type: Application
    Filed: February 14, 2022
    Publication date: September 1, 2022
    Inventors: Michel LAGARDE, Evelyne VERICEL, Madeleine PICQ, Michel GUICHARDANT, Nathalie BERNOUD-HUBAC, Baptiste FOURMAUX
  • ACEFAPC FOR THE TREATMENT OF ACETYLCHOLINE-DEPENDENT DISEASES
    Publication number: 20200054653
    Abstract: The present invention relates to AceFaPC (1-Acetyl-2-Fatty acyl-glyceroPhosphoCholine) for use in the prevention and treatment of diseases associated with an acetylcholine deficiency. The invention also relates to the AceFaPC molecule in which Fa represents an unsaturated acyl comprising at least 14 carbon atoms, and the pharmaceutical compositions comprising same.
    Type: Application
    Filed: March 8, 2018
    Publication date: February 20, 2020
    Inventors: Michel LAGARDE, Evelyne VERICEL, Madeleine PICQ, Michel GUICHARDANT, Nathalie BERNOUD-HUBAC, Baptiste FOURMAUX
  • Methods of treating diabetic retinopathy with pericyte apoptosis inhibitors
    Patent number: 8119609
    Abstract: A method of preventing or treating diabetic retinopathy is disclosed including administering to a mammal a therapeutically effective amount of an inhibitor of retinal pericyte apoptosis. Also disclosed is a pharmaceutical composition which treats and/or prevents diabetic retinopathy comprising as an active agent a therapeutically effective amount of at least one inhibitor of retinal pericyte apoptosis and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 23, 2003
    Date of Patent: February 21, 2012
    Assignees: Merck Sante, INSERM
    Inventors: Marc Lecomte, Ulriche Denis, Clarisse Paget, Nicolas Wiernsperger, Michel Lagarde
  • Gm3 Synthase as a Therapeutic Target in Microvascular Complications of Diabetes
    Publication number: 20070224200
    Abstract: The present invention relates to the use of an inhibitor of the expression or activity of the GM3 synthase gene for the treatment of microvascular complications of diabetes, and to a method of screening compounds useful in the treatment and/or prevention of these complications.
    Type: Application
    Filed: April 7, 2005
    Publication date: September 27, 2007
    Inventors: Samer Elbawab, Elodie Masson, Daniel Ruggiero, Nicolas Wiernsperger, Michel Lagarde, Lysiane Troncy
  • Methods and compositions of treating and/or preventing diabetic retinopathy with pericyte apoptosis inhibitors
    Publication number: 20030216290
    Abstract: A method of preventing or treating diabetic retinopathy is disclosed including administering to a mammal a therapeutically effective amount of an inhibitor of retinal pericyte apoptosis. Also disclosed is a pharmaceutical composition which treats and/or prevents diabetic retinopathy comprising as an active agent a therapeutically effective amount of at least one inhibitor of retinal pericyte apoptosis and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 23, 2003
    Publication date: November 20, 2003
    Applicants: Merck Sante, a corporation of France, INSERM, a corporation of France
    Inventors: Marc Lecomte, Ulriche Denis, Clarisse Paget, Nicolas Wiernsperger, Michel Lagarde
  • Polyunsaturated fatty acid based drugs
    Patent number: 5654290
    Abstract: Drug compositions comprised of therapeutically effective amounts of at least one compound selected from the group consisting of:DHA esterified in the form of lysophosphatidyl-choline (lyso-PCDHA) in position sn-2;DHA-phosphatidylcholines (PCDHAs) in which DHA is esterified in position sn-2 and which have an acyl group of [very short length] 2 to 6 carbon atoms in position sn-1;and triglycerides in which DHA is esterified in position sn-2 and which have acyl groups of [very short length] 2 to 6 carbon atoms in positions sn-1 and sn-3.
    Type: Grant
    Filed: September 21, 1994
    Date of Patent: August 5, 1997
    Assignees: Institut National de la Sante et de la Recherche Medicale, Imedex
    Inventors: Yves Bayon, Martine Croset, Michel Lagarde, Jean Lecerf, Frank Thies, Jean-Louis Tayot, Veronique Chirouze
  • Isolation of stearidonic acid from fatty acid mixtures
    Patent number: 5130449
    Abstract: Substantially pure stearidonic acid is isolated from a mixture of polyunsaturated fatty acids by fractionating at 25% to 35% by weight solution of fatty acids by high-performance reverse-phase liquid chromatography using a mobile phase of 75% to 95% by weight methanol and 25% to 5% by weight water. The isolated stearidonic acid is used to prepare pharmaceutical compositions which are administered to treat cardiovascular and thrombo-embolic diseases associated with platelet aggregation.
    Type: Grant
    Filed: May 9, 1990
    Date of Patent: July 14, 1992
    Assignee: Nestec S.A.
    Inventors: Michel Lagarde, Helmut Traitler, Hans-Juergen Wille